What question did this study set out to answer?

This research aims to determine the optimal treatment for acute ischemic stroke in late therapeutic windows, focusing on efficacy and safety.

February 2, 2026

Abstract DP076: Thrombectomy vs Thrombolysis vs Bridging Therapy in Late-Window Stroke with Salvageable Tissue: A Network Meta-Analysis of Randomized Controlled Trials

Key Points

This research aims to determine the optimal treatment for acute ischemic stroke in late therapeutic windows, focusing on efficacy and safety.
Conducted a network meta-analysis of randomized controlled trials (RCTs)
Systematically searched databases including MEDLINE and EMBASE
Included studies with patients experiencing anterior circulation large vessel occlusion in late window
Assessed primary outcome of functional independence and secondary outcomes related to disability and hemorrhage risk
Fifteen trials with 4,497 patients included in the analysis
EVT reduced 90-day mortality compared to alteplase and tenecteplase
EVT associated with better functional outcomes; lower rates of severe disability and intracranial hemorrhage
Rankings indicated EVT consistently superior for both efficacy and safety

Abstract

Background: For patients presenting with acute ischemic stroke in the late therapeutic window (>4.5 hours), the optimal treatment strategy remains debated. We conducted a network meta-analysis comparing endovascular thrombectomy, thrombolysis with alteplase or tenecteplase, and best medical therapy in patients with salvageable tissue, focusing on both efficacy and safety outcomes. Methods: We systematically searched MEDLINE, EMBASE, Scopus, Cochrane Library through July 2025, identifying RCTs enrolling adults with anterior circulation large vessel occlusion in the late window based on CT/MR perfusion imaging. A random-effects network meta-analysis compared EVT, alteplase, tenecteplase, and best medical therapy. Primary outcome was functional independence; secondary outcomes included severe disability/death, mortality, and symptomatic intracranial hemorrhage. Results: Fifteen trials enrolling 4,497 patients were included. Time-to-treatment across studies was 10.05 ± 4.78 hours. EVT was associated with significantly reduced 90-day mortality compared to alteplase (OR 0.41; 95% CI 0.19–0.89) and better functional outcomes (mRS 0–2 OR 2.12; 95% CI 0.75–5.98). EVT also reduced the odds of mRS 5–6 (OR 0.42; 95% CI 0.18–1.00) and showed a numerically favorable safety profile over alteplase in sICH risk (OR 0.39; 95% CI 0.08–1.91). Compared with tenecteplase, EVT lowered mortality (OR 0.61; 95% CI 0.38–0.98) with comparable efficacy. Tenecteplase had a lower sICH risk than alteplase (OR 0.27; 95% CI 0.05–1.57). Rankograms showed EVT consistently ranked highest for efficacy and safety. Conclusion: In patients with salvageable tissue presenting in the late window, EVT provides superior efficacy and safety compared to thrombolysis or medical therapy alone. Tenecteplase may offer safety advantages over alteplase. These findings support prioritizing EVT access and rapid imaging in late-presenting stroke.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Huu et al. (Thu,) studied this question.

synapsesocial.com/papers/6980fc91c1c9540dea80e677 https://doi.org/https://doi.org/10.1161/str.57.suppl_1.dp076

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper